eli lilly glp 1 pipeline set to leapfrog Novo Nordisk in weight-loss drug race GLP-1 Pipeline Update: February 2026
Description
Rev Gastroenterol Mex (Engl Ed) 2024
To bolster its oncology pipeline, Novartis acquired oncology biotech MorphoSys for $2.9 billion in 2024
Gastric inhibitory polypeptide (GIP) dosedependently stimulates glucagon secretion in healthy human subjects at euglycaemia
These signs could actually point to gastroparesis
Elvert R, Herling AW, Bossart M, Weiss T, Zhang B, Wenski P, et al
Recently, some GLP-1 agents have become popular weight loss medications
